39541-91-8

Basic information

• Product Name: 2-Methyl-4-(3-nitro-phenyl)-thiazole
• Synonyms: 2-Methyl-4-(3-nitro-phenyl)-thiazole;3-(2-Methyl-1,3-thiazol-4-yl)nitrobenzene
• CAS NO: 39541-91-8
• Molecular Formula: C₁₀H₈N₂O₂S
• Molecular Weight: 220.25
• Mol File: 39541-91-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methyl-4-(3-nitro-phenyl)-thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-4-(3-nitro-phenyl)-thiazole(39541-91-8)
• EPA Substance Registry System: 2-Methyl-4-(3-nitro-phenyl)-thiazole(39541-91-8)

Safety Data

• Hazardous Substances Data: 39541-91-8(Hazardous Substances Data)

Upstream product

• 99-47-8 2-chloro-1-(3-nitrophenyl)ethanone 
• 62-55-5 thioacetamide 
• 2227-64-7 3'-nitro-2-bromoacetophenone 

Downstream Products

• 89250-34-0 3-(2-methyl-thiazol-4-yl)-phenylamine 
• 570431-14-0 (2-chloromethyl-6,7-diethoxy-quinazolin-4-yl)-[3-(2-methyl-thiazol-4-yl)-phenyl]-amine 

Relevant articles and documents

IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

A novel and efficient one pot synthesis of 2,4-disubstituted thiazoles and oxazoles using phenyltrimethylammoniumtribromide in ionic liquid

A novel and efficient one-pot procedure has been described for synthesis of 2,4-disubstituted thiazoles and oxazoles from substituted ketones using phenyltrimethylammoniumtribromide as in situ brominating agent followed by reaction with thioamide/thiourea and amides/ureas, respectively in [bmim][BF4] ionicliquid. The advantages of the procedure include avoiding the handling of lacrymetric compounds, hazardous and toxic organic solvents along with good to excellent yield of the products.

Fructose 1,6-bisphosphatase inhibitors

The present invention relates to certain quinazoline compounds which have utility in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer. The invention also relates to pharmaceutical compositions and